封面
市場調查報告書
商品編碼
1610267

肺炎治療藥物市場:按藥物類別、肺炎類型、年齡層、分銷管道分類 - 全球預測 2025-2030

Pneumonia Therapeutics Market by Drug Class, Pneumonia Type (Community-acquired pneumonia, Hospital-acquired pneumonia, Ventilator-associated pneumonia ), Age Group, Distribution Channel - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肺炎藥物市值為153.4億美元,預計到2024年將達到166.4億美元,複合年成長率為8.93%,到2030年將達到279.3億美元。

肺炎治療市場包括旨在對抗肺炎的多種治療和預防措施,肺炎是一種影響肺部且主要由感染疾病引起的發炎疾病。該系列包括抗生素、疫苗和其他旨在減輕症狀和根除感染的治療方法。肺炎的高發病率和死亡率凸顯了對有效治療的需求,特別是在幼兒、老年人和免疫力缺乏等弱勢群體中。肺炎藥物不僅用於治療,還用於透過疫苗接種進行預防,凸顯了預防醫學在醫療保健系統中的重要性。最終用途主要集中在醫院、診所和居家醫療機構,重點關注治療的可近性和有效性,以減少住院時間並改善患者的治療效果。影響該市場的關鍵成長要素包括人口老化導致的肺炎發病率增加和慢性病的流行,從而對先進治療解決方案產生了持續的需求。此外,研究技術的進步和醫療保健支出的增加正在創造重要的創新機會,特別是在開發新型疫苗和抗生素療法方面,重點是克服抗生素抗藥性。然而,市場開拓受到高昂的治療開發成本、嚴格的監管核准以及疫苗猶豫不決的新威脅等因素的阻礙。潛在的創新領域包括探索個人化醫療方法和利用人工智慧來更好地管理患者。對新藥物傳輸系統的研究和增強現有疫苗以涵蓋更廣泛的病原體也可能推動市場進步。透過這種方式,公司可以利用與生技公司的夥伴關係關係,投資於突破性治療方法的研發,並專注於對成本效益市場需求較高的新興市場進行擴張。

主要市場統計
基準年[2023] 153.4億美元
預計年份 [2024] 166.4億美元
預測年份 [2030] 279.3億美元
複合年成長率(%) 8.93%

市場動態:快速發展的肺炎藥物市場的關鍵市場洞察

供需的動態交互作用正在改變肺炎藥物市場。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 肺炎盛行率不斷上升,需要有效的治療
    • 大量投入肺炎治療藥物研發
    • 增加具有成本效益的非專利肺炎治療方法
  • 市場限制因素
    • 肺炎治療時間延長
  • 市場機會
    • 新技術改善肺炎診斷和治療
    • 越來越重視個人化醫療以生產高效藥物
  • 市場挑戰
    • 某些肺炎治療可能產生的副作用

波特五力:駕馭肺炎藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解肺炎藥物市場的外部影響

外部宏觀環境因素對肺炎治療藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肺炎治療藥物市場的競爭狀況

對肺炎治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣性肺炎藥物市場供應商的績效評估

FPNV定位矩陣是評估肺炎治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商,從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商,並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議,描繪肺炎治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說,對肺炎治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機,並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:全面分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肺炎的傳播和有效治療的需要
      • 大量投入肺炎治療藥物研發
      • 提高非專利成本效益的肺炎通用治療方法的可用性
    • 抑制因素
      • 肺炎治療時間延長
    • 機會
      • 新技術改善肺炎診斷和治療
      • 個人化醫療對於高效藥物生產變得越來越重要
    • 任務
      • 某些肺炎治療的潛在副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的肺炎治療藥物市場

  • 抗生素
  • 抗真菌藥物
  • 抗病毒藥物

第7章 依肺炎類型分類的肺炎治療藥物市場

  • 社區型肺炎(CAP)
  • 院內獲得性肺炎 (HAP)
  • 人工呼吸器相關性肺炎(VAP)

第8章肺炎治療藥物市場:依年齡層

  • 成人用
  • 老年病
  • 小兒科

第9章肺炎治療藥物市場:按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 北美及南美肺炎治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太肺炎藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東、非洲肺炎藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Allergan plc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biobrick Pharma
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Lincoln Pharmaceuticals Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus UK Limited by CSL Limited
  • Serum Institute of India
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wellona Pharma
  • Zydus Healthcare Limited
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market was valued at USD 15.34 billion in 2023, expected to reach USD 16.64 billion in 2024, and is projected to grow at a CAGR of 8.93%, to USD 27.93 billion by 2030.

The pneumonia therapeutics market encompasses a wide array of medical treatments and preventative measures designed to combat pneumonia, an inflammatory condition affecting the lungs primarily caused by infections. This scope includes antibiotics, vaccines, and other treatment modalities aimed at alleviating symptoms and eradicating infection. The necessity for effective pneumonia therapeutics is underscored by the disease's significant morbidity and mortality rates, particularly among vulnerable populations such as young children, the elderly, and immunocompromised individuals. Applications of pneumonia therapeutics extend beyond treatment to encompass prevention through vaccination, underlying the importance of preventative care in healthcare systems. End-use is primarily concentrated in hospitals, clinics, and home healthcare settings, where the focus is on accessibility and efficacy of treatments to reduce hospital stays and improve patient outcomes. Key growth factors influencing this market include rising incidence rates of pneumonia due to aging populations and the increasing prevalence of chronic diseases, creating a sustained demand for advanced therapeutic solutions. Additionally, developments in research technology and increased healthcare spending present substantial opportunities for innovation, particularly in the development of novel vaccines and antibiotic therapies, with an emphasis on overcoming antibiotic resistance. However, market growth is constrained by factors such as high costs of treatment development, stringent regulatory approvals, and the emerging threat of vaccine hesitancy. Potential areas for innovation include exploring personalized medicine approaches and leveraging AI for better patient management. Emphasizing the research of new drug delivery systems and enhancing existing vaccines to cover a broader spectrum of pathogens could also stimulate market advances. Thus, businesses can capitalize on partnerships with biotech firms, invest in R&D for breakthrough therapies, and focus on expanding their reach in emerging markets where the demand for cost-effective pneumonia therapeutics is high, all within a competitive yet promising market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 15.34 billion
Estimated Year [2024] USD 16.64 billion
Forecast Year [2030] USD 27.93 billion
CAGR (%) 8.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pneumonia Therapeutics Market

The Pneumonia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of pneumonia and the need for efficient treatment
    • Significant investments in research & development of pneumonia-therapeutics
    • Increasing availability of generic and cost-effective pneumonia drugs
  • Market Restraints
    • Prolonged treatment duration for pneumonia
  • Market Opportunities
    • Emerging technologies to improve diagnosis and treatment of pneumonia
    • Growing emphasis on personalized medicine for the production of efficient drugs
  • Market Challenges
    • Potential side effects associated with certain pneumonia therapies

Porter's Five Forces: A Strategic Tool for Navigating the Pneumonia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pneumonia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pneumonia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pneumonia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pneumonia Therapeutics Market

A detailed market share analysis in the Pneumonia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pneumonia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pneumonia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pneumonia Therapeutics Market

A strategic analysis of the Pneumonia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pneumonia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan plc, AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Biobrick Pharma, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lincoln Pharmaceuticals Ltd., Lupin Pharmaceuticals, Inc., Mankind Pharma Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Seqirus UK Limited by CSL Limited, Serum Institute of India, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Wellona Pharma, and Zydus Healthcare Limited.

Market Segmentation & Coverage

This research report categorizes the Pneumonia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antibacterial Drugs, Antifungal Drugs, and Antiviral Drugs.
  • Based on Pneumonia Type, market is studied across Community-acquired pneumonia (CAP), Hospital-acquired pneumonia (HAP), and Ventilator-associated pneumonia (VAP).
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatrics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of pneumonia and the need for efficient treatment
      • 5.1.1.2. Significant investments in research & development of pneumonia-therapeutics
      • 5.1.1.3. Increasing availability of generic and cost-effective pneumonia drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Prolonged treatment duration for pneumonia
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging technologies to improve diagnosis and treatment of pneumonia
      • 5.1.3.2. Growing emphasis on personalized medicine for the production of efficient drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects associated with certain pneumonia therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pneumonia Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antibacterial Drugs
  • 6.3. Antifungal Drugs
  • 6.4. Antiviral Drugs

7. Pneumonia Therapeutics Market, by Pneumonia Type

  • 7.1. Introduction
  • 7.2. Community-acquired pneumonia (CAP)
  • 7.3. Hospital-acquired pneumonia (HAP)
  • 7.4. Ventilator-associated pneumonia (VAP)

8. Pneumonia Therapeutics Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatrics

9. Pneumonia Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Pneumonia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumonia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumonia Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Allergan plc
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. Bayer AG
  • 6. Biobrick Pharma
  • 7. Cipla Limited
  • 8. Dr. Reddy's Laboratories Ltd.
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlaxoSmithKline PLC
  • 12. Hikma Pharmaceuticals PLC
  • 13. Lincoln Pharmaceuticals Ltd.
  • 14. Lupin Pharmaceuticals, Inc.
  • 15. Mankind Pharma Ltd.
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Seqirus UK Limited by CSL Limited
  • 21. Serum Institute of India
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Viatris Inc.
  • 25. Wellona Pharma
  • 26. Zydus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. PNEUMONIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PNEUMONIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PNEUMONIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBACTERIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY-ACQUIRED PNEUMONIA (CAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA (HAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR-ASSOCIATED PNEUMONIA (VAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PNEUMONIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023